viernes, 18 de julio de 2008

Prevención y Control de la Influenza

Este reporte del Comite Asesor sobre Practicas de Inmunización (ACIP) de la CDC actualiza las recomendaciones sobre la VACUNA PARA INFLUENZA Y AGENTES ANTIVIRALES.

The 2008 recommendations include new and updated information. Principal updates and changes include 1) a new recommendation that annual vaccination be administered to all children aged 5--18 years, beginning in the 2008--09 influenza season, if feasible, but no later than the 2009--10 influenza season; 2) a recommendation that annual vaccination of all children aged 6 months through 4 years (59 months) continue to be a primary focus of vaccination efforts because these children are at higher risk for influenza complications compared with older children; 3) a new recommendation that either trivalent inactivated influenza vaccine or live, attenuated influenza vaccine (LAIV) be used when vaccinating healthy persons aged 2 through 49 years (the previous recommendation was to administer LAIV to person aged 5--49 years); 4) a recommendation that vaccines containing the 2008--09 trivalent vaccine virus strains A/Brisbane/59/2007 (H1N1)-like, A/Brisbane/10/2007 (H3N2)-like, and B/Florida/4/2006-like antigens be used; and, 5) new information on antiviral resistance among influenza viruses in the United States. Persons for whom vaccination is recommended are listed in boxes 1 and 2. These recommendations also include a summary of safety data for U.S. licensed influenza vaccines. This report and other information are available at CDC's influenza website (http://www.cdc.gov/flu), including any updates or supplements to these recommendations that might be required during the 2008--09 influenza season. Vaccination and health-care providers should be alert to announcements of recommendation updates and should check the CDC influenza website periodically for additional information.

Suero Antibotrópico Liofilizado - PERU

El Instituto Nacional de Salud oficializó el Lanzamiento del Suero Antibotrópico Liofilizado el cual fue desarrollado por el Centro Nacional de Productos Biológicos (CNPB) luego de más de 8 años de esfuerzo, y que en el último año se ha convertido en una realidad.
Cabe señalar que en el Perú anualmente se registran más de 2000 accidentes por mordedura de serpiente, siendo la del género Bothrops “Jergón” la que reporta mayor cantidad de casos a nivel nacional principalmente en las zonas rurales selváticas, desérticas y semidesérticas de la costa; por ello, existe la necesidad de acercar los sueros antiofídicos a los lugares más recónditos del país